Literature DB >> 26290102

An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia.

Denise C Cornelius1, Lorena M Amaral1, Ashlyn Harmon1, Kedra Wallace2, Alexia J Thomas1, Nathan Campbell1, Jeremy Scott1, Florian Herse3, Nadine Haase3, Janae Moseley1, Gerd Wallukat3, Ralf Dechend3, Babbette LaMarca4.   

Abstract

The reduced uterine perfusion pressure (RUPP) rat model of preeclampsia exhibits much of the pathology characterizing this disease, such as hypertension, inflammation, suppressed regulatory T cells (TRegs), reactive oxygen species (ROS), and autoantibodies to the ANG II type I receptor (AT1-AA) during pregnancy. The objective of this study was to determine whether supplementation of normal pregnant (NP) TRegs into RUPP rats would attenuate the pathophysiology associated with preeclampsia during pregnancy. CD4(+)/CD25(+) T cells were isolated from spleens of NP and RUPP rats, cultured, and injected into gestation day (GD) 12 normal pregnant rats that underwent the RUPP procedure on GD 14. On GD 1, mean arterial pressure (MAP) was recorded, and blood and tissues were collected for analysis. One-way ANOVA was used for statistical analysis. MAP increased from 99 ± 2 mmHg in NP (n = 12) to 127 ± 2 mmHg in RUPP (n = 21) but decreased to 118 ± 2 mmHg in RUPP+NP TRegs (n = 17). Circulating IL-6 and IL-10 were not significantly changed, while circulating TNF-α and IL-17 were significantly decreased after supplementation of TRegs. Placental and renal ROS were 339 ± 58.7 and 603 ± 88.1 RLU·min(-1)·mg(-1) in RUPP and significantly decreased to 178 ± 27.8 and 171 ± 55.6 RLU·min(-1)·mg(-1), respectively, in RUPP+NP TRegs; AT1-AA was 17.81 ± 1.1 beats per minute (bpm) in RUPP but was attenuated to 0.50 ± 0.3 bpm with NP TRegs. This study demonstrates that NP TRegs can significantly improve inflammatory mediators, such as IL-17, TNF-α, and AT1-AA, which have been shown to increase blood pressure during pregnancy.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  hypertension; inflammation; oxidative stress; pregnancy; regulatory T cells

Mesh:

Substances:

Year:  2015        PMID: 26290102      PMCID: PMC4666948          DOI: 10.1152/ajpregu.00154.2015

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  46 in total

Review 1.  Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia.

Authors:  Ralf Dechend; Volker Homuth; Gerd Wallukat; Dominik N Müller; Manja Krause; Joachim Dudenhausen; Hermann Haller; Friedrich C Luft
Journal:  J Soc Gynecol Investig       Date:  2006-02

Review 2.  Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Jeffery Gilbert; Joey P Granger
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

3.  Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes.

Authors:  Babbette LaMarca; Kedra Wallace; Florian Herse; Gerd Wallukat; James N Martin; Abram Weimer; Ralf Dechend
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

Review 4.  Placental cytokines and the pathogenesis of preeclampsia.

Authors:  K P Conrad; D F Benyo
Journal:  Am J Reprod Immunol       Date:  1997-03       Impact factor: 3.886

5.  Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats.

Authors:  Babbette LaMarca; Gerd Wallukat; Mayte Llinas; Florian Herse; Ralf Dechend; Joey P Granger
Journal:  Hypertension       Date:  2008-10-13       Impact factor: 10.190

6.  Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade.

Authors:  Babbette LaMarca; Josh Speed; Lillian Fournier; Sara A Babcock; Hunter Berry; Kathy Cockrell; Joey P Granger
Journal:  Hypertension       Date:  2008-11-03       Impact factor: 10.190

7.  Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.

Authors:  Babbette LaMarca; Marc Parrish; Lillian Fournier Ray; Sydney R Murphy; Lyndsay Roberts; Porter Glover; Gerd Wallukat; Katrin Wenzel; Kathy Cockrell; James N Martin; Michael J Ryan; Ralf Dechend
Journal:  Hypertension       Date:  2009-08-24       Impact factor: 10.190

8.  In vitro expansion of CD4+CD25highFOXP3+CD127low/- regulatory T cells from peripheral blood lymphocytes of healthy Mycobacterium tuberculosis-infected humans.

Authors:  Jean-Michel Hougardy; Virginie Verscheure; Camille Locht; Françoise Mascart
Journal:  Microbes Infect       Date:  2007-06-30       Impact factor: 2.700

9.  Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia.

Authors:  Brigitte Santner-Nanan; Michael John Peek; Roma Khanam; Luise Richarts; Erhua Zhu; Barbara Fazekas de St Groth; Ralph Nanan
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

Review 10.  Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin?

Authors:  Babbette D LaMarca; Barbara T Alexander; Jeffery S Gilbert; Michael J Ryan; Mona Sedeek; Sydney R Murphy; Joey P Granger
Journal:  Gend Med       Date:  2008
View more
  34 in total

1.  Tumor necrosis factor-α impairs cerebral blood flow in pregnant rats: role of vascular β-epithelial Na+ channel.

Authors:  Jeremy W Duncan; Subhi Talal Younes; Emily Hildebrandt; Michael J Ryan; Joey P Granger; Heather A Drummond
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-03-13       Impact factor: 4.733

Review 2.  Regulatory T cells in embryo implantation and the immune response to pregnancy.

Authors:  Sarah A Robertson; Alison S Care; Lachlan M Moldenhauer
Journal:  J Clin Invest       Date:  2018-10-01       Impact factor: 14.808

3.  Decreased homodimerization and increased TIMP-1 complexation of uteroplacental and uterine arterial matrix metalloproteinase-9 during hypertension-in-pregnancy.

Authors:  Juanjuan Chen; Zongli Ren; Minglin Zhu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2017-05-12       Impact factor: 5.858

Review 4.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

Review 5.  Inflammatory mediators: a causal link to hypertension during preeclampsia.

Authors:  Denise C Cornelius; Jesse Cottrell; Lorena M Amaral; Babbette LaMarca
Journal:  Br J Pharmacol       Date:  2018-09-28       Impact factor: 8.739

6.  Increased vascular and uteroplacental matrix metalloproteinase-1 and -7 levels and collagen type I deposition in hypertension in pregnancy: role of TNF-α.

Authors:  Wei Li; Ning Cui; Marc Q Mazzuca; Karina M Mata; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

Review 7.  Novel adaptive and innate immunity targets in hypertension.

Authors:  Justine M Abais-Battad; John Henry Dasinger; Daniel J Fehrenbach; David L Mattson
Journal:  Pharmacol Res       Date:  2017-03-20       Impact factor: 7.658

8.  Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction.

Authors:  Bhavisha A Bakrania; Frank T Spradley; Heather A Drummond; Babbette LaMarca; Michael J Ryan; Joey P Granger
Journal:  Compr Physiol       Date:  2020-12-09       Impact factor: 9.090

9.  Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia.

Authors:  J S Possomato-Vieira; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-06-14

Review 10.  Identifying immune mechanisms mediating the hypertension during preeclampsia.

Authors:  Babbette LaMarca; Denise C Cornelius; Ashlyn C Harmon; Lorena M Amaral; Mark W Cunningham; Jessica L Faulkner; Kedra Wallace
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-04-20       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.